Barinthus Biotherapeutics PLBRNS
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 18 institutions reported holding Barinthus Biotherapeutics PL (BRNS) in their 13F filings, up 3 from Q1 2024. 3 opened new positions and 0 sold out. The largest holders were M&G PLC ($5.2M), Alphabet Inc. ($2.1M) and HSG Holding Ltd ($1.9M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Barinthus Biotherapeutics PL
- CUSIP
- 91864C107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $53K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 223,027 shares bought and 6,589 shares sold, net +216,438 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| M&G PLC | 0.04% | No change | 5,197,349 | $5.2M |
| Alphabet Inc. | 0.11% | No change | 1,513,644 | $2.1M |
| HSG Holding Ltd | 0.07% | No change | 1,420,473 | $1.9M |
| DC Funds, LP | 14.93% | No change | 642,204 | $899K |
| BlueCrest Capital Management Ltd | 0.21% | No change | 542,673 | $760K |
| Baird Financial Group, Inc. | 0.00% | Add +59.6% | 267,705 | $375K |
| Johns Hopkins University | 0.01% | No change | 122,237 | $171K |
| UBS Group AG | 0.00% | Add +5501.4% | 86,653 | $121K |
| Renaissance Technologies | 0.00% | Reduce -9.4% | 25,100 | $35K |
| Ipswich Investment Management Co., Inc. | 0.01% | No change | 23,075 | $32K |
| Catalina Capital Group, LLC | 0.01% | New | 17,819 | $25K |
| Citadel Advisors | 0.00% | New | 16,037 | $22K |
| Janney Montgomery Scott LLC | 0.00% | No change | 15,008 | $21K |
| Geode Capital Management, LLC | 0.00% | No change | 11,568 | $16K |
| Morgan Stanley | 0.00% | Reduce -31.0% | 8,873 | $12K |
| Royal Bank of Canada | 0.00% | New | 4,065 | $6K |
| New England Capital Financial Advisors LLC | 0.00% | No change | 104 | $146 |
| Rhumbline Advisers | 0.00% | No change | 60 | $84 |
"% of holder's portfolio" is BRNS's weight in each manager's 13F, not the share of Barinthus Biotherapeutics PL the manager owns.